Inhibition of Rab Prenylation

Enzymes

Volumn 30, Issue , 2011, Pages 179-203

  Anouk Stigter, E ^a,b   Triola, Gemma ^a,b   Goody, Roger S ^a   Waldmann, Herbert ^a,b  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

Author keywords

GGTI 2Z; Peptide analogs; Phosphonocarboxylates; Pyrrolidine based inhibitors; RabGGTase inhibitors; Tetrahydrobenzodiazepines

Indexed keywords

EID: 81255192057     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-415922-8.00008-2     Document Type: Chapter

References (43)

1. Oldham W.M., Van Eps N., Preininger A.M., et al. Mechanism of the receptor-catalyzed activation of heterotrimeric G proteins. Nat Struct Mol Biol 2006, 13:772-777.
2. Wennerberg K., Rossman K.L., Der C.J. The Ras superfamily at a glance. J Cell Sci 2005, 118:843-846.
3. Gilman A.G. G-proteins-transducers of receptor-generated signals. Annu Rev Biochem 1987, 56:615-649.
4. Takai Y., Sasaki T., Matozaki T. Small GTP-binding proteins. Physiol Rev 2001, 81:153-208.
5. Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE 2004, 2004:re13.
6. Reiss Y., Seabra M.C., Armstrong S.A., et al. Nonidentical subunits of p21(H-ras) farnesyltransferase peptide binding and farnesyl pyrophosphate carrier functions. J Biol Chem 1991, 266:10672-10677.
7. Seabra M.C., Goldstein J.L., Sudhof T.C., et al. Rab geranylgeranyl transferase A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys. J Biol Chem 1992, 267:14497-14503.
8. Seabra M.C., Reiss Y., Casey P.J., et al. Protein farnesyltransferase and geranylgeranyltransferase share a common α subunit. Cell 1991, 65:429-434.
9. Fu H.W., Casey P.J. Enzymology and biology of CaaX protein prenylation. Recent Prog Horm Res 1999, 54:315-343.
10. Lane K.T., Beese L.S. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res 2006, 47:681-699.
11. Leung K.F., Baron R., Seabra M.C. Thematic review series: lipid posttranslational modifications geranylgeranylation of Rab GTPases. J Lipid Res 2006, 47:467-475.
12. Goody R.S., Rak A., Alexandrov K. The structural and mechanistic basis for recycling of Rab proteins between membrane compartments. Cell Mol Life Sci 2005, 62:1657-1670.
13. Sistonen L., Alitalo K. Activation of c-ras oncogenes by mutations and amplification. Ann Clin Res 1986, 18:297-303.
14. Withers S.T., Keasling J.D. Biosynthesis and engineering of isoprenoid small molecules. Appl Microbiol Biotechnol 2007, 73:980-990.
15. Mabuchi H., Nohara A., Kobayashi J., et al. Coenzyme Q10 reduction with statins: another pleiotropic effect. Curr Drug Ther 2007, 2:39-51.
16. Sebti S.M., Hamilton A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000, 19:6584-6593.
17. Gibbs R.A., Zahn T.J., Sebolt-Leopold J.S. Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms. Curr Med Chem 2001, 8:1437-1465.
18. El Oualid F., Cohen L.H., van der Marel G.A., et al. Inhibitors of protein: geranylgeranyl transferases. Curr Med Chem 2006, 13:2385-2427.
19. Konstantinopoulos P.A., Karamouzis M.V., Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007, 6:540-555.
20. Basso A.D., Kirschmeier P., Bishop W.R. Farnesyl transferase inhibitors. J Lipid Res 2006, 47:15-31.
21. Kazi A., Carie A., Blaskovich M.A., et al. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol Cell Biol 2009, 29:2254-2263.
22. Lackner M.R., Kindt R.M., Carroll P.M., et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 2005, 7:325-336.
23. Zerial M., McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2001, 2:107-117.
24. Cheng K.W., Lahad J.P., Kuo W.L., et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat. Med. (NY, USA) 2004, 10:1251-1256.
25. Croizet-Berger K., Daumerie C., Couvreur M., et al. The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production. Proc Natl Acad Sci USA 2002, 99:8277-8282.
26. Tan K.T., Guiu-Rozas E., Bon R.S., et al. Design, synthesis, and characterization of peptide-based Rab geranylgeranyl transferase inhibitors. J Med Chem 2009, 52:8025-8037.
27. Coxon F.P., Thompson K., Rogers M.J. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006, 6:307-312.
28. Coxon F.P., Helfrich M.H., Larijani B., et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 2001, 276:48213-48222.
29. Lawson M.A., Coulton L., Ebetino F.H., et al. Geranylgeranyl transferase type II inhibition prevents myeloma bone disease. Biochem Biophys Res Commun 2008, 377:453-457.
30. Roelofs A.J., Hulley P.A., Meijer A., et al. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer 2006, 119:1254-1261.
31. Marma M.S., Xia Z., Stewart C., et al. Synthesis and biological evaluation of α-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem 2007, 50:5967-5975.
32. Coxon F.P., Ebetino F.H., Mules E.H., et al. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 2005, 37:349-358.
33. Baron R.A., Tavare R., Figueiredo A.C., et al. Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase. J Biol Chem 2009, 284:6861-6868.
34. McKenna C.E., Kashemirov B.A., Blazewska K.M., et al. Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem 2010, 53:3454-3464.
35. Sane K.M., Mynderse M., LaLonde D.T., et al. A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. J Pharmacol Exp Ther 2010, 333:23-33.
36. Castellano S., Fiji H.D.G., Kinderman S.S., et al. Small-molecule inhibitors of protein geranylgeranyltransferase type I. J Am Chem Soc 2007, 129:5843-5845.
37. Watanabe M., Fiji H.D.G., Guo L., et al. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 2008, 283:9571-9579.
38. Nguyen U.T.T., Guo Z., Delon C., et al. Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. Nat Chem Biol 2009, 5:227-235.
39. Guo Z., Wu Y.W., Tan K.T., et al. Development of selective RabGGTase inhibitors and crystal structure of a RabGGTase-inhibitor complex. Angew Chem Int Ed Engl 2008, 47:3747-3750.
40. Wu Y.W., Waldmann H., Reents R., et al. A protein fluorescence amplifier: continuous fluorometric assay for Rab geranylgeranyltransferase. Chem Bio Chem 2006, 7:1859-1861.
41. Dursina B., Reents R., Delon C., et al. Identification and specificity profiling of protein prenyltransferase inhibitors using new fluorescent phosphoisoprenoids. J Am Chem Soc 2006, 128:2822-2835.
42. Rose W.C., Lee F.Y.F., Fairchild C.R., et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res 2001, 61:7507-7517.
43. Bon R.S., Guo Z., Stigter E.A., et al. Structure-guided development of selective RabGGTase inhibitors. Angew Chem Int Ed 2011, 50:4957-4961.